DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis

NASDAQ:DVAX • US2681582019

15.5 USD
0 (0%)
At close: Feb 9, 2026
15.5 USD
0 (0%)
After Hours: 2/9/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

DVAX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. DVAX has an average financial health and profitability rating. DVAX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, DVAX could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year DVAX was profitable.
  • In the past year DVAX had a positive cash flow from operations.
  • In multiple years DVAX reported negative net income over the last 5 years.
  • Of the past 5 years DVAX 4 years had a positive operating cash flow.
DVAX Yearly Net Income VS EBIT VS OCF VS FCFDVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

1.2 Ratios

  • DVAX's Return On Assets of -4.59% is amongst the best of the industry. DVAX outperforms 86.40% of its industry peers.
  • DVAX's Return On Equity of -8.13% is amongst the best of the industry. DVAX outperforms 88.70% of its industry peers.
  • With an excellent Return On Invested Capital value of 1.05%, DVAX belongs to the best of the industry, outperforming 89.08% of the companies in the same industry.
Industry RankSector Rank
ROA -4.59%
ROE -8.13%
ROIC 1.05%
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
DVAX Yearly ROA, ROE, ROICDVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • In the last couple of years the Profit Margin of DVAX has declined.
  • DVAX has a better Operating Margin (3.16%) than 89.46% of its industry peers.
  • Looking at the Gross Margin, with a value of 83.17%, DVAX belongs to the top of the industry, outperforming 86.21% of the companies in the same industry.
  • DVAX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 3.16%
PM (TTM) N/A
GM 83.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
DVAX Yearly Profit, Operating, Gross MarginsDVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DVAX is destroying value.
  • Compared to 1 year ago, DVAX has less shares outstanding
  • DVAX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, DVAX has a worse debt to assets ratio.
DVAX Yearly Shares OutstandingDVAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DVAX Yearly Total Debt VS Total AssetsDVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • DVAX has an Altman-Z score of 2.44. This is not the best score and indicates that DVAX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • DVAX has a Altman-Z score of 2.44. This is in the better half of the industry: DVAX outperforms 67.24% of its industry peers.
  • DVAX has a debt to FCF ratio of 3.24. This is a good value and a sign of high solvency as DVAX would need 3.24 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.24, DVAX belongs to the best of the industry, outperforming 92.34% of the companies in the same industry.
  • A Debt/Equity ratio of 0.49 indicates that DVAX is not too dependend on debt financing.
  • DVAX has a Debt to Equity ratio of 0.49. This is in the lower half of the industry: DVAX underperforms 69.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 3.24
Altman-Z 2.44
ROIC/WACC0.13
WACC8.24%
DVAX Yearly LT Debt VS Equity VS FCFDVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 7.62 indicates that DVAX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 7.62, DVAX is doing good in the industry, outperforming 72.99% of the companies in the same industry.
  • DVAX has a Quick Ratio of 6.94. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
  • DVAX has a Quick ratio of 6.94. This is in the better half of the industry: DVAX outperforms 69.92% of its industry peers.
Industry RankSector Rank
Current Ratio 7.62
Quick Ratio 6.94
DVAX Yearly Current Assets VS Current LiabilitesDVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 211.54% over the past year.
  • DVAX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.10% yearly.
  • Looking at the last year, DVAX shows a very strong growth in Revenue. The Revenue has grown by 26.73%.
  • Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 51.10% on average per year.
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%

3.2 Future

  • The Earnings Per Share is expected to grow by 63.12% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, DVAX will show a quite strong growth in Revenue. The Revenue will grow by 15.42% on average per year.
EPS Next Y-318.17%
EPS Next 2Y72.81%
EPS Next 3Y63.12%
EPS Next 5YN/A
Revenue Next Year21.89%
Revenue Next 2Y18.83%
Revenue Next 3Y17.54%
Revenue Next 5Y15.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
DVAX Yearly Revenue VS EstimatesDVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DVAX Yearly EPS VS EstimatesDVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • DVAX is valuated quite expensively with a Price/Earnings ratio of 37.80.
  • DVAX's Price/Earnings ratio is rather cheap when compared to the industry. DVAX is cheaper than 91.95% of the companies in the same industry.
  • DVAX's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.98.
  • A Price/Forward Earnings ratio of 28.84 indicates a quite expensive valuation of DVAX.
  • Based on the Price/Forward Earnings ratio, DVAX is valued cheaply inside the industry as 91.76% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. DVAX is around the same levels.
Industry RankSector Rank
PE 37.8
Fwd PE 28.84
DVAX Price Earnings VS Forward Price EarningsDVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DVAX is valued cheaper than 90.61% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DVAX is valued cheaper than 95.02% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.88
EV/EBITDA 66.27
DVAX Per share dataDVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • DVAX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as DVAX's earnings are expected to grow with 63.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.81%
EPS Next 3Y63.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DVAX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DYNAVAX TECHNOLOGIES CORP

NASDAQ:DVAX (2/9/2026, 8:00:01 PM)

After market: 15.5 0 (0%)

15.5

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-18
Inst Owners98.72%
Inst Owner Change-0.68%
Ins Owners0.71%
Ins Owner Change-2122.58%
Market Cap1.76B
Revenue(TTM)330.51M
Net Income(TTM)-43.40M
Analysts80
Price Target20.91 (34.9%)
Short Float %8.69%
Short Ratio2.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.4%
Min EPS beat(2)30.1%
Max EPS beat(2)64.71%
EPS beat(4)3
Avg EPS beat(4)6.21%
Min EPS beat(4)-86.66%
Max EPS beat(4)64.71%
EPS beat(8)6
Avg EPS beat(8)-6.9%
EPS beat(12)9
Avg EPS beat(12)66.09%
EPS beat(16)11
Avg EPS beat(16)67.73%
Revenue beat(2)1
Avg Revenue beat(2)3.46%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-0.31%
Min Revenue beat(4)-4.19%
Max Revenue beat(4)7.97%
Revenue beat(8)2
Avg Revenue beat(8)-2.29%
Revenue beat(12)6
Avg Revenue beat(12)3.06%
Revenue beat(16)8
Avg Revenue beat(16)4.4%
PT rev (1m)-1.2%
PT rev (3m)-14.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45%
EPS NY rev (1m)0%
EPS NY rev (3m)12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE 37.8
Fwd PE 28.84
P/S 5.33
P/FCF 21.88
P/OCF 19.44
P/B 3.3
P/tB 3.31
EV/EBITDA 66.27
EPS(TTM)0.41
EY2.65%
EPS(NY)0.54
Fwd EY3.47%
FCF(TTM)0.71
FCFY4.57%
OCF(TTM)0.8
OCFY5.14%
SpS2.91
BVpS4.7
TBVpS4.68
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.58
Profitability
Industry RankSector Rank
ROA -4.59%
ROE -8.13%
ROCE 1.24%
ROIC 1.05%
ROICexc 3.98%
ROICexgc 4.02%
OM 3.16%
PM (TTM) N/A
GM 83.17%
FCFM 24.37%
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 3.24
Debt/EBITDA 20.41
Cap/Depr 429.21%
Cap/Sales 3.05%
Interest Coverage 2.16
Cash Conversion 708.62%
Profit Quality N/A
Current Ratio 7.62
Quick Ratio 6.94
Altman-Z 2.44
F-Score5
WACC8.24%
ROIC/WACC0.13
Cap/Depr(3y)139.55%
Cap/Depr(5y)160.56%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)211.54%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-318.17%
EPS Next 2Y72.81%
EPS Next 3Y63.12%
EPS Next 5YN/A
Revenue 1Y (TTM)26.73%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%17.67%
Revenue Next Year21.89%
Revenue Next 2Y18.83%
Revenue Next 3Y17.54%
Revenue Next 5Y15.42%
EBIT growth 1Y240.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year458.87%
EBIT Next 3Y103.78%
EBIT Next 5YN/A
FCF growth 1Y-31.63%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-25.53%
OCF growth 3Y-41.69%
OCF growth 5YN/A

DYNAVAX TECHNOLOGIES CORP / DVAX FAQ

What is the fundamental rating for DVAX stock?

ChartMill assigns a fundamental rating of 6 / 10 to DVAX.


Can you provide the valuation status for DYNAVAX TECHNOLOGIES CORP?

ChartMill assigns a valuation rating of 6 / 10 to DYNAVAX TECHNOLOGIES CORP (DVAX). This can be considered as Fairly Valued.


How profitable is DYNAVAX TECHNOLOGIES CORP (DVAX) stock?

DYNAVAX TECHNOLOGIES CORP (DVAX) has a profitability rating of 6 / 10.


Can you provide the financial health for DVAX stock?

The financial health rating of DYNAVAX TECHNOLOGIES CORP (DVAX) is 6 / 10.